Acutaas Chemicals Limited vs Rubicon Research Limited
An objective side-by-side of ACUTAAS and RUBICON, both in Pharmaceuticals: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-12 close
Latest results: ACUTAAS Sep 2026 · RUBICON Sep 2026
At a glance
- Acutaas Chemicals Limited is the larger company by market value, about 1.2 times the size of Rubicon Research Limited.
- On trailing earnings, Acutaas Chemicals Limited trades at the lower P/E (74.7 against 87.5).
- Acutaas Chemicals Limited earns the higher return on equity (23.6% against 22.9%).
- Over the past year the share prices returned +125.8% (ACUTAAS) and +169.0% (RUBICON).
| Metric | Acutaas Chemicals ACUTAAS |
Rubicon Research RUBICON |
|---|---|---|
| Size and price | ||
| Market cap | ₹32,717 Cr | ₹28,428 Cr |
| Share price | ₹3,996.10 | ₹1,717.30 |
| Valuation | ||
| P/E | 74.67 | 87.47 |
| P/B | 17.61 | 20.07 |
| EV/EBITDA | 52.45 | 57.82 |
| Profitability | ||
| ROE | 23.6% | 22.9% |
| Operating margin | 39.2% | 23.8% |
| Sales (TTM) | ₹1,593 Cr | ₹2,100 Cr |
| Net profit (TTM) | ₹438 Cr | ₹325 Cr |
| Growth | ||
| Latest quarter sales YoY | +42.7% | +39.9% |
| Latest quarter profit YoY | +71.4% | +67.9% |
| Financial strength | ||
| Debt/Equity | 0.01 | 0.35 |
| Interest cover | 138.23 | 8.41 |
| Ownership | ||
| Promoter holding | 32.7% | 51.2% |
| Price performance | ||
| Return 1M | +27.10% | +11.50% |
| Return 3M | +23.11% | +3.76% |
| Return 1Y | +125.78% | +168.96% |
| Return YTD | +134.39% | +152.27% |
| Technical condition | ||
| Technical score | 80 | 74 |
| RS rating (1-99) | 95.00 | 96.00 |
| % vs 200-DMA | +37.56% | +38.10% |
| RSI (14) | 67.97 | 58.79 |
| % from 52-week high | -3.01% | -9.57% |
